Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases

Cell Host and Microbe

Volumn 21, Issue 5, 2017, Pages 603-610.e3

  Ananthakrishnan, Ashwin N ^a,b   Luo, Chengwei ^c   Yajnik, Vijay ^a,b   Khalili, Hamed ^a,b   Garber, John J ^a   Stevens, Betsy W ^b   Cleland, Thomas ^a   Xavier, Ramnik J ^a,b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d Massachusetts Institute of Technology   (United States)

Author keywords

butyrate; Microbiome; remission; roseburia; treatment response; vedolizumab

Indexed keywords

BUTYRIC ACID DERIVATIVE; INTEGRIN; MONOCLONAL ANTIBODY; VEDOLIZUMAB;

BIOLOGICAL THERAPY; CHEMISTRY; CROHN DISEASE; DRUG EFFECTS; FECES; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; METABOLISM; METAGENOME; MICROBIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; BUTYRATES; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; INTEGRINS; METAGENOME; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85019108860     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2017.04.010     Document Type: Article

References (49)

1. Abubucker, S., Segata, N., Goll, J., Schubert, A.M., Izard, J., Cantarel, B.L., Rodriguez-Mueller, B., Zucker, J., Thiagarajan, M., Henrissat, B., et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput. Biol., 8, 2012, e1002358.
2. Ananthakrishnan, A.N., Huang, H., Nguyen, D.D., Sauk, J., Yajnik, V., Xavier, R.J., Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. Am. J. Gastroenterol. 109 (2014), 395–400.
3. Arijs, I., Li, K., Toedter, G., Quintens, R., Van Lommel, L., Van Steen, K., Leemans, P., De Hertogh, G., Lemaire, K., Ferrante, M., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58 (2009), 1612–1619.
4. Baumgart, D.C., Sandborn, W.J., Crohn's disease. Lancet 380 (2012), 1590–1605.
5. Becker, C., Neurath, M.F., Wirtz, S., The intestinal microbiota in inflammatory bowel disease. ILAR J. 56 (2015), 192–204.
6. Bolger, A.M., Lohse, M., Usadel, B., Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30 (2014), 2114–2120.
7. Brezinski, E.A., Dhillon, J.S., Armstrong, A.W., Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 151 (2015), 651–658.
8. Buchfink, B., Xie, C., Huson, D.H., Fast and sensitive protein alignment using DIAMOND. Nat. Methods 12 (2015), 59–60.
9. Canani, R.B., Costanzo, M.D., Leone, L., Pedata, M., Meli, R., Calignano, A., Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J. Gastroenterol. 17 (2011), 1519–1528.
10. Castro-Rueda, H., Kavanaugh, A., Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr. Opin. Rheumatol. 20 (2008), 314–319.
11. Coburn, L.A., Gong, X., Singh, K., Asim, M., Scull, B.P., Allaman, M.M., Williams, C.S., Rosen, M.J., Washington, M.K., Barry, D.P., et al. L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis. PLoS One, 7, 2012, e33546.
12. Colombel, J.F., Rutgeerts, P., Reinisch, W., Esser, D., Wang, Y., Lang, Y., Marano, C.W., Strauss, R., Oddens, B.J., Feagan, B.G., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141 (2011), 1194–1201.
13. Cross, M., Smith, E., Hoy, D., Carmona, L., Wolfe, F., Vos, T., Williams, B., Gabriel, S., Lassere, M., Johns, N., et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann. Rheum. Dis. 73 (2014), 1316–1322.
14. D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008), 660–667.
15. Eppinga, H., Konstantinov, S.R., Peppelenbosch, M.P., Thio, H.B., The microbiome and psoriatic arthritis. Curr. Rheumatol. Rep., 16, 2014, 407.
16. Forbes, J.D., Van Domselaar, G., Bernstein, C.N., The Gut Microbiota in Immune-Mediated Inflammatory Diseases. Front. Microbiol., 7, 2016, 1081.
17. Gevers, D., Kugathasan, S., Denson, L.A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S.J., Yassour, M., et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15 (2014), 382–392.
18. Haiser, H.J., Gootenberg, D.B., Chatman, K., Sirasani, G., Balskus, E.P., Turnbaugh, P.J., Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341 (2013), 295–298.
19. Hamer, H.M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F.J., Brummer, R.J., Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 27 (2008), 104–119.
20. Harvey, R.F., Bradshaw, J.M., A simple index of Crohn's-disease activity. Lancet, 1, 1980, 514.
21. Inan, M.S., Rasoulpour, R.J., Yin, L., Hubbard, A.K., Rosenberg, D.W., Giardina, C., The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 118 (2000), 724–734.
22. Integrative, H.M.P.R.N.C., Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16 (2014), 276–289.
23. Knights, D., Lassen, K.G., Xavier, R.J., Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 62 (2013), 1505–1510.
24. Kolios, G., Valatas, V., Ward, S.G., Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 113 (2004), 427–437.
25. Kostic, A.D., Xavier, R.J., Gevers, D., The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146 (2014), 1489–1499.
26. Langmead, B., Salzberg, S.L., Fast gapped-read alignment with Bowtie 2. Nat. Methods 9 (2012), 357–359.
27. Lee, H.S., Han, S.Y., Ryu, K.Y., Kim, D.H., The degradation of glycosaminoglycans by intestinal microflora deteriorates colitis in mice. Inflammation 32 (2009), 27–36.
28. Lewis, J.D., Chen, E.Z., Baldassano, R.N., Otley, A.R., Griffiths, A.M., Lee, D., Bittinger, K., Bailey, A., Friedman, E.S., Hoffmann, C., et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric crohn's disease. Cell Host Microbe 18 (2015), 489–500.
29. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
30. Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W., Kaplan, G.G., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.e42 quiz e30.
31. Neville, B.A., Sheridan, P.O., Harris, H.M., Coughlan, S., Flint, H.J., Duncan, S.H., Jeffery, I.B., Claesson, M.J., Ross, R.P., Scott, K.P., O'Toole, P.W., Pro-inflammatory flagellin proteins of prevalent motile commensal bacteria are variably abundant in the intestinal microbiome of elderly humans. PLoS One, 8, 2013, e68919.
32. Ordás, I., Eckmann, L., Talamini, M., Baumgart, D.C., Sandborn, W.J., Ulcerative colitis. Lancet 380 (2012), 1606–1619.
33. Pardee, K., Green, A.A., Ferrante, T., Cameron, D.E., DaleyKeyser, A., Yin, P., Collins, J.J., Paper-based synthetic gene networks. Cell 159 (2014), 940–954.
34. Pavlidis, P., Gulati, S., Dubois, P., Chung-Faye, G., Sherwood, R., Bjarnason, I., Hayee, B., Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease. Scand. J. Gastroenterol. 51 (2016), 1447–1452.
35. Peterson, J., Garges, S., Giovanni, M., McInnes, P., Wang, L., Schloss, J.A., Bonazzi, V., McEwen, J.E., Wetterstrand, K.A., Deal, C., et al., NIH HMP Working Group. The NIH human microbiome project. Genome Res. 19 (2009), 2317–2323.
36. Ramasundara, M., Leach, S.T., Lemberg, D.A., Day, A.S., Defensins and inflammation: the role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol. 24 (2009), 202–208.
37. Ramiro, S., Smolen, J.S., Landewé, R., van der Heijde, D., Dougados, M., Emery, P., de Wit, M., Cutolo, M., Oliver, S., Gossec, L., Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann. Rheum. Dis. 75 (2016), 490–498.
38. Rutgeerts, P., Goboes, K., Peeters, M., Hiele, M., Penninckx, F., Aerts, R., Kerremans, R., Vantrappen, G., Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338 (1991), 771–774.
39. Shaw, K.A., Bertha, M., Hofmekler, T., Chopra, P., Vatanen, T., Srivatsa, A., Prince, J., Kumar, A., Sauer, C., Zwick, M.E., et al. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Med., 8, 2016, 75.
40. Shelton, E., Allegretti, J.R., Stevens, B., Lucci, M., Khalili, H., Nguyen, D.D., Sauk, J., Giallourakis, C., Garber, J., Hamilton, M.J., et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm. Bowel Dis. 21 (2015), 2879–2885.
41. Siegel, C.A., Melmed, G.Y., Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap. Adv. Gastroenterol. 2 (2009), 245–251.
42. Singh, S., Graff, L.A., Bernstein, C.N., Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?. Am. J. Gastroenterol. 104 (2009), 1298–1313 quiz 1314.
43. Singh, J.A., Saag, K.G., Bridges, S.L. Jr., Akl, E.A., Bannuru, R.R., Sullivan, M.C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R.H., et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68 (2016), 1–26.
44. Truong, D.T., Franzosa, E.A., Tickle, T.L., Scholz, M., Weingart, G., Pasolli, E., Tett, A., Huttenhower, C., Segata, N., MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat. Methods 12 (2015), 902–903.
45. Ungaro, R., Bernstein, C.N., Gearry, R., Hviid, A., Kolho, K.L., Kronman, M.P., Shaw, S., Van Kruiningen, H., Colombel, J.F., Atreja, A., Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am. J. Gastroenterol. 109 (2014), 1728–1738.
46. Upchurch, K.S., Kay, J., Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 51:Suppl 6 (2012), vi28–vi36.
47. Walmsley, R.S., Ayres, R.C., Pounder, R.E., Allan, R.N., A simple clinical colitis activity index. Gut 43 (1998), 29–32.
48. Wu, H.J., Ivanov, I.I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D.R., Benoist, C., Mathis, D., Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32 (2010), 815–827.
49. Zimmerman, M.A., Singh, N., Martin, P.M., Thangaraju, M., Ganapathy, V., Waller, J.L., Shi, H., Robertson, K.D., Munn, D.H., Liu, K., Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am. J. Physiol. Gastrointest. Liver Physiol. 302 (2012), G1405–G1415.